Compare KG & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KG | ACET |
|---|---|---|
| Founded | N/A | 1947 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.3M | 83.3M |
| IPO Year | 2025 | 2017 |
| Metric | KG | ACET |
|---|---|---|
| Price | $7.37 | $9.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $48.33 |
| AVG Volume (30 Days) | 22.1K | ★ 74.1K |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1819.15 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $34,049,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 785.08 | N/A |
| 52 Week Low | $6.72 | $0.46 |
| 52 Week High | $29.13 | $9.97 |
| Indicator | KG | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 58.39 |
| Support Level | N/A | $7.45 |
| Resistance Level | $8.17 | $9.59 |
| Average True Range (ATR) | 0.53 | 0.52 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 46.79 | 66.67 |
Kestrel Group Ltd specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers with two reportable segments: Program Services and Legacy Reinsurance. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).